271 related articles for article (PubMed ID: 34795058)
21. Fbxo22 promotes cervical cancer progression via targeting p57
Lin M; Zhang J; Bouamar H; Wang Z; Sun LZ; Zhu X
Cell Death Dis; 2022 Sep; 13(9):805. PubMed ID: 36127346
[TBL] [Abstract][Full Text] [Related]
22. FBXO22, ubiquitination degradation of PHLPP1, ameliorates rotenone induced neurotoxicity by activating AKT pathway.
Zheng X; Yu S; Xue Y; Yan F
Toxicol Lett; 2021 Oct; 350():1-9. PubMed ID: 34182063
[TBL] [Abstract][Full Text] [Related]
23. E3 ubiquitin ligase FBXW7 enhances radiosensitivity of non-small cell lung cancer cells by inhibiting SOX9 regulation of CDKN1A through ubiquitination.
Zhu H; Wang X; Zhou X; Lu S; Gu G; Liu C
Lab Invest; 2022 Nov; 102(11):1203-1213. PubMed ID: 35840806
[TBL] [Abstract][Full Text] [Related]
24. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y
Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532
[TBL] [Abstract][Full Text] [Related]
25. FBXO22 protein is required for optimal synthesis of the N-methyl-D-aspartate (NMDA) receptor coagonist D-serine.
Dikopoltsev E; Foltyn VN; Zehl M; Jensen ON; Mori H; Radzishevsky I; Wolosker H
J Biol Chem; 2014 Dec; 289(49):33904-15. PubMed ID: 25336657
[TBL] [Abstract][Full Text] [Related]
26. Z-guggulsterone induces PD-L1 upregulation partly mediated by FXR, Akt and Erk1/2 signaling pathways in non-small cell lung cancer.
Tian H; Gui Y; Wei Y; Shang B; Sun J; Ma S; You W; Jiang S
Int Immunopharmacol; 2021 Apr; 93():107395. PubMed ID: 33529916
[TBL] [Abstract][Full Text] [Related]
27. FBXO22 inhibits proliferation and metastasis of cervical cancer cells by mediating ubiquitination-dependent degradation of GAK.
Li S; Shi L; Wang Y; Zhang L; Chu S; Li M; Bai J; Zhu W
Exp Cell Res; 2023 Sep; 430(1):113719. PubMed ID: 37442264
[TBL] [Abstract][Full Text] [Related]
28. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y
J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543
[TBL] [Abstract][Full Text] [Related]
29. Tumour cell-intrinsic CTLA4 regulates PD-L1 expression in non-small cell lung cancer.
Zhang H; Dutta P; Liu J; Sabri N; Song Y; Li WX; Li J
J Cell Mol Med; 2019 Jan; 23(1):535-542. PubMed ID: 30378264
[TBL] [Abstract][Full Text] [Related]
30. Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer.
Kim SJ; Kim S; Kim DW; Kim M; Keam B; Kim TM; Lee Y; Koh J; Jeon YK; Heo DS
Cancer Res Treat; 2019 Jul; 51(3):1231-1240. PubMed ID: 30653748
[TBL] [Abstract][Full Text] [Related]
31. FBXO22 Suppresses Metastasis in Human Renal Cell Carcinoma via Inhibiting MMP-9-Mediated Migration and Invasion and VEGF-Mediated Angiogenesis.
Guo F; Liu J; Han X; Zhang X; Lin T; Wang Y; Bai J; Han J
Int J Biol Sci; 2019; 15(3):647-656. PubMed ID: 30745851
[TBL] [Abstract][Full Text] [Related]
32. E3 ubiquitin ligases Cbl-b and c-Cbl downregulate PD-L1 in EGFR wild-type non-small cell lung cancer.
Wang S; Xu L; Che X; Li C; Xu L; Hou K; Fan Y; Wen T; Qu X; Liu Y
FEBS Lett; 2018 Feb; 592(4):621-630. PubMed ID: 29364514
[TBL] [Abstract][Full Text] [Related]
33. Comparison of
Erber R; Stöhr R; Herlein S; Giedl C; Rieker RJ; Fuchs F; Ficker JH; Hartmann A; Veltrup E; Wirtz RM; Brueckl WM
Anticancer Res; 2017 Dec; 37(12):6771-6778. PubMed ID: 29187455
[TBL] [Abstract][Full Text] [Related]
34. F-box protein FBXO22 mediates polyubiquitination and degradation of KLF4 to promote hepatocellular carcinoma progression.
Tian X; Dai S; Sun J; Jin G; Jiang S; Meng F; Li Y; Wu D; Jiang Y
Oncotarget; 2015 Sep; 6(26):22767-75. PubMed ID: 26087183
[TBL] [Abstract][Full Text] [Related]
35. Down-regulation of RCC1 sensitizes immunotherapy by up-regulating PD-L1 via p27
Zeng X; Zhong M; Yang Y; Wang Z; Zhu Y
J Cell Mol Med; 2021 Apr; 25(8):4136-4147. PubMed ID: 33630417
[TBL] [Abstract][Full Text] [Related]
36. Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments.
Omori S; Kenmotsu H; Abe M; Watanabe R; Sugino T; Kobayashi H; Nakashima K; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Ohde Y; Endo M; Akiyama Y; Nakajima T; Takahashi T
Int J Clin Oncol; 2018 Dec; 23(6):1052-1059. PubMed ID: 29948239
[TBL] [Abstract][Full Text] [Related]
37. Molecular regulatory network of PD-1/PD-L1 in non-small cell lung cancer.
Lingling Z; Jiewei L; Li W; Danli Y; Jie Z; Wen L; Dan P; Lei P; Qinghua Z
Pathol Res Pract; 2020 Apr; 216(4):152852. PubMed ID: 32057515
[TBL] [Abstract][Full Text] [Related]
38. MYC expression correlates with PD-L1 expression in non-small cell lung cancer.
Kim EY; Kim A; Kim SK; Chang YS
Lung Cancer; 2017 Aug; 110():63-67. PubMed ID: 28676221
[TBL] [Abstract][Full Text] [Related]
39. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
[TBL] [Abstract][Full Text] [Related]
40. PD-L1 sustains chronic, cancer cell-intrinsic responses to type I interferon, enhancing resistance to DNA damage.
Cheon H; Holvey-Bates EG; McGrail DJ; Stark GR
Proc Natl Acad Sci U S A; 2021 Nov; 118(47):. PubMed ID: 34799452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]